VEGF and NLR as Diagnostic Biomarkers in Malignant, Non-Malignant, and Tuberculosis Pleural Effusion Patients
DOI:
https://doi.org/10.15395/mkb.v58.4412Keywords:
Malignant pleural effusion, neutrophil to lymphocyte ratio, vascular endothelial growth factorAbstract
Differentiating malignant from non-malignant pleural effusions, as well as distinguishing malignancy from tuberculosis, remains challenging and carries significant diagnostic and therapeutic implications. This study aimed to analyze vascular endothelial growth factor (VEGF) level and the neutrophil-to-lymphocyte ratio (NLR) in pleural fluid as potential diagnostic biomarkers. A cross-sectional analytical observational study conducted using purposive sampling. A total 110 patients were divided into three groups, and VEGF and NLR levels were measured from pleural fluid samples. Data were analyzed using the Kruskal–Wallis test followed by Dunn's post-hoc test. Results demonstrated that VEGF levels among the three groups differed significantly (p=0.000). The VEGF level was highest in the malignant pleural effusion (MPE) group at 6,916.80 pg/mL, compared with 4,544.49 pg/mL in the Non-MPE (NMPE) and 1,936.61 pg/mL in the tuberculosis group. Receiver operating characteristic (ROC) curve analysis showed that VEGF had the highest diagnostic accuracy in differentiating malignant from non-malignant effusion (AUC: 80.8%, p=0.000), and for distinguishing malignant from tuberculosis effusion (AUC: 76.8%; p=0.000). In contrast, NLR did not demonstrate meaningful diagnostic performance. Although the VEGF levels were elevated across all groups (MPE, NMPE, and tuberculosis), they were significantly higher in malignant effusions. VEGF demonstrated high sensitivity and specificity as a diagnostic biomarker for differentiating MPE, NMPE, and tuberculosis-related effusions. Thus, VEGF shows good potential as a diagnostic biomarker for identifying MPE, whereas NLR does not demonstrate usefulness as a diagnostic biomarker.
Downloads
References
1. Adeoye PO, Johnson WR, Desalu OO, Ofoegbu CP, Fawibe AE, Salami AK,et al. Etiology, clinical characteristics, and management of pleural effusion in Ilorin, Nigeria. Nigerian Medical Journal. 2017;58(2):76. doi:10.4103/0300–1652.219349
2. Jany B, Welte T. Pleural effusion in adults—etiology, diagnosis, and treatment. Dtsch Arztebl Int. 2019. doi:10.3238/arztebl.2019.0377
3. Tian P, Qiu R, Wang M, Xu S, Cao L, Yang P, et al. Prevalence, causes, and health care burden of pleural effusions among hospitalized adults in China. JAMA Netw Open. 2021;4(8):e2120306. doi:10.1001/jamanetworkopen.2021.20306
4. Skok K, Hladnik G, Grm A, Crnjac A. Malignant pleural effusion and its current management: a review. Medicina (B Aires). 2019;55(8):490. doi:10.3390/medicina55080490
5. Allama AM, Abou-Elela DH, Ibrahim IM. Pleural and serum markers for diagnosis of malignant pleural effusion. Asian Cardiovasc Thorac Ann. 2020;28(9):560–5. doi:10.1177/0218492320948311
6. Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–67.
7. Chen Y, Mathy N, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with nonsmall cell lung cancer (Review). Mol Med Rep. 2018. doi:10.3892/mmr.2018.8922
8. Demir U. The relation of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and mean platelet volume with idiopathic acute anterior uveitis. Eur J Inflamm. 2024;22. doi:10.1177/1721727X231216196
9. El-Sokkary RT, Abuelkassem NM, Seddik MI, Metwally A. New biomarkers for the diagnosis of pleural effusion. The Egyptian Journal of Bronchology. 2022;16(1):38. doi:10.1186/s43168–022–00137–7
10. Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I, et al. Prognostic factors in patients presenting with pleural effusion revealing malignancy. Respiration. 2014;87(4):311–6. doi:10.1159/000356764
11. Zaki HA, Albaroudi B, Shaban EE, Shaban A, Elgassim M, Almarri ND, et al. Advancement in pleura effusion diagnosis: a systematic review and meta-analysis of point-of-care ultrasound versus radiographic thoracic imaging. Ultrasound J. 2024;16(1):3. doi:10.1186/s13089–023–00356-z
12. Saha BK, Chong WH, Austin A, Kathuria R, Datar P, Shkolnik B, Beegle S, et al. Pleural abnormalities in COVID-19: a narrative review. J Thorac Dis. 2021;13(7):4484–99. doi:10.21037/jtd-21–542
13. Magkouta S, Glynos K, Pappas A, Papapetropoulos A, Kalomenidis I. Effect of smoking on experimental malignant pleural effusion. In: 11.2 Pleural and Mediastinal Malignancies. European Respiratory Society; 2015:PA4343. doi:10.1183/13993003.congress-2015.PA4343
14. Psatha A, Makris D, Kerenidi T, Daniil Z, Kiropoulos T, Gourgoulianis K. A potential role for VEGF in the diagnostic approach of pleural effusions. J Thorac Dis. 2016;8(7):1681–7. doi:10.21037/jtd.2016.05.73
15. Khalil NH, Abdelaal DE. Vascular endothelial growth factor in diagnosis of pleural effusion. Egyptian Journal of Chest Diseases and Tuberculosis. 2017;66(1):115–9. doi:10.1016/j.ejcdt.2016.12.006
16. Ewida E, Abd Elnaby HE, Deraz E, Alzohairy Y. Diagnostic value of neutrophil-lymphocyte ratio in exudative pleural effusion. Al-Azhar International Medical Journal. 2022;3(11):119–24. doi:10.21608/aimj.2022.137606.1940
17. Akturk UA, Ernam D, Akbay MO, Koçak ND, Ogur E, Irmak I. Role of the neutrophil-lymphocyte ratio in the differential diagnosis of exudative pleural effusion. Clinics. 2016;71(10):611–16. doi:10.6061/clinics/2016(10)10
18. Barata I, Amir Z, Siagian P, Eyanoer PC, Lubis Z. Sensitivity comparison of pleural fluid and serum neutrophil to lymphocyte ratio (NLR) values in exudative pleural effusion patients. Jurnal Respirologi Indonesia. 2020;40(4):232–7. doi:10.36497/jri.v40i4.131
19. Tavares F, Moraes PIM, Souza JM, Barbosa AH, Santos EM, Marcondes JA, et al. Prognostic role of neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing to pharmaco-invasive strategy. Cardiovascular Revascularization Medicine. 2022;34:99–103. doi:10.1016/j.carrev.2021.01.027
20. Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019;9. doi:10.3389/fonc.2019.01146
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Majalah Kedokteran Bandung
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
Under this license, authors retain copyright and grant Majalah Kedokteran Bandung the right of first publication. Others may share, remix, and adapt the work for non-commercial purposes, provided that appropriate credit is given to the author and to Majalah Kedokteran Bandung as the initial place of publication.
For details, please see: https://creativecommons.org/licenses/by-nc/4.0/
